Skip to content
In Stock Colchicine
Gout

Colchicine

Colchicine, the active ingredient of Colchicine tablets, is an anti-inflammatory treatment used mainly for acute gout flares and gout-flare prevention. It reduces the inflammatory reaction caused by…

Guaranteed quality Original product
Delivery: from 4 days Discreet shipping
24/7 Support Always available
Active ingredient: Colchicine
Select pack Package Per unit Price
$ 3.26 $ 195.80
$ 2.69 $ 293.70 $ 242.08 Save 18%
$ 2.39 $ 391.60 $ 286.58 Save 27%
Free Regular Delivery $ 2.12 $ 587.40 $ 380.92 Save 35%
Free Regular Delivery $ 1.91 $ 881.10 $ 516.20 Save 41%
Best value Free Express Delivery $ 1.82 $ 1,174.80 $ 656.82 Save 44%

Free delivery on orders from $ 356.00, free express delivery from $ 534.00

Secure payment methods:
VISA AMEX JCB DISCOVER

Colchicine, the active ingredient of Colchicine tablets, is an anti-inflammatory treatment used mainly for acute gout flares and gout-flare prevention. It reduces the inflammatory reaction caused by urate crystals in joints, helping limit pain and swelling when prescribed at an individually selected dose.

Product information

Colchicine is a specific anti-inflammatory medicine supplied here as 500 microgram tablets. Its main clinical use is gout, where monosodium urate crystals activate immune cells inside a joint. Colchicine does not remove uric acid from the body; it suppresses the inflammatory response triggered by the crystals.

Ingredients

Colchicine tablets contain colchicine as the active ingredient, supplied here as 500 microgram tablets. The formulation does not remove uric acid; colchicine suppresses the inflammatory response triggered by monosodium urate crystals.

Therapeutic indications

Doctors may prescribe Colchicine for:

  • Treatment of an acute gout flare.
  • Prevention of gout flares when starting or adjusting urate-lowering treatment.
  • Selected inflammatory conditions where colchicine has an established specialist role.
  • Familial Mediterranean fever, where authorised and clinically appropriate.
  • Other indications only when a prescriber has assessed the expected benefit and toxicity risk.

Directions for use

Colchicine tablets are taken by mouth. The prescribed dose is decided individually, taking age, other medicines and health conditions into account.

  • Take the tablets only at the frequency prescribed for the specific condition.
  • Swallow the tablet with water unless a prescriber has given different instructions.
  • Do not increase the dose because joint pain remains severe.
  • Do not repeat a dose early after vomiting without obtaining specific medical advice.
  • Do not combine separate colchicine-containing products.
  • If a dose is missed, take the next dose according to the prescribed schedule unless a clinician has given different instructions.
  • Do not take two doses together to compensate for a missed dose.

The amount needed for gout treatment is not determined by body weight alone. Age, kidney function, liver function, blood disorders and interacting medicines can change colchicine exposure. People with reduced kidney or liver function may need a lower dose, a longer interval between doses or avoidance of treatment.

Keep a written record of when each tablet was taken during an acute flare. This simple step helps prevent accidental repeat dosing when pain and poor sleep make timing difficult.

When not to use it

  • Severe kidney impairment.
  • Severe liver impairment.
  • Existing blood-count abnormalities or bone-marrow disease.
  • Significant neuromuscular disease.
  • Pregnancy or breastfeeding, where the expected benefit and risk require individual assessment.
  • Previous serious reaction to colchicine.
  • Concurrent use of strong CYP3A4 or P-glycoprotein inhibitors.

Examples of interacting medicines include clarithromycin, erythromycin, certain azole antifungals, ciclosporin, some HIV medicines and selected calcium-channel blockers. Grapefruit products may also affect drug transport or metabolism in some circumstances. The exact risk depends on the medicine, dose and organ function.

Statins and fibrates can increase concern about muscle injury when used with colchicine. This does not mean that every combination is prohibited, but new muscle pain, weakness or dark urine needs rapid assessment.

When this is not for you

Colchicine is not suitable for everyone. It is not for you if you have a known allergy to colchicine or if a prescriber has identified a contraindication related to your kidney, liver, blood or medicine history.

Do not take colchicine during an acute illness involving severe dehydration without medical advice. Dehydration can worsen kidney clearance and raise exposure.

Unwanted effects

The most familiar adverse effects are gastrointestinal. Diarrhoea, nausea, vomiting and abdominal pain can occur because colchicine affects rapidly renewing cells in the digestive tract as well as inflammatory cells.

Common or clinically relevant problems include:

  • Diarrhoea.
  • Nausea or vomiting.
  • Abdominal pain or cramping.
  • Reduced appetite.
  • Fatigue.
  • Muscle pain or weakness.
  • Reduced blood-cell production with excessive exposure or prolonged toxicity.

Severe diarrhoea or repeated vomiting is not a sign that the medicine is simply “working strongly”. It can indicate toxicity, especially when kidney function is reduced or an interacting medicine has been added. Muscle weakness, numbness, dark urine, unusual bruising, fever or marked lethargy require urgent medical assessment.

Colchicine toxicity may progress to bone-marrow suppression, neuromuscular injury, organ failure or death. The risk increases with overdose, impaired clearance and medicines that inhibit CYP3A4 or P-glycoprotein.

One practical detail is easy to miss: muscle toxicity can appear gradually rather than as sudden severe pain. New difficulty climbing stairs, rising from a chair or lifting ordinary objects deserves attention.

Mechanism of action

Colchicine binds to tubulin, a protein that forms microtubules inside cells. Microtubules act like an internal transport and movement system. When colchicine disrupts their assembly, neutrophils have greater difficulty moving towards urate crystals and releasing inflammatory substances.

This action affects several stages of gout inflammation:

  • Neutrophil migration towards the joint becomes less active.
  • Neutrophil adhesion and activation are reduced.
  • Release of inflammatory mediators decreases.
  • Assembly of inflammatory protein complexes, including the NLRP3 inflammasome, is suppressed.
  • The joint response to urate crystals becomes less intense.

The NLRP3 inflammasome is a cellular alarm system. When activated by urate crystals, it helps generate interleukin-1 beta, a major driver of gout inflammation.

The European Medicines Agency describes colchicine toxicity as dose-related, which is why kidney function, liver function and interacting medicines matter [1].

Common mistakes

Several avoidable errors can make colchicine treatment unsafe or less useful.

  • Taking extra tablets because pain has not eased quickly.
  • Continuing repeated doses despite severe diarrhoea.
  • Forgetting to mention antibiotics, antifungals or transplant medicines.
  • Using an old dosing plan after kidney function has changed.
  • Taking tablets from two different colchicine prescriptions on the same day.
  • Assuming that colchicine lowers uric acid permanently.
  • Stopping long-term preventive treatment without discussing the treatment plan.
  • Ignoring new muscle weakness because the joint pain has improved.

Patients sometimes focus on the painful toe and overlook the rest of the body. Colchicine toxicity can affect the gastrointestinal tract, muscles, nerves and bone marrow, so symptoms outside the joint matter.

A second common mistake is treating all “low-dose” regimens as identical. A cardiovascular regimen, a gout-prevention regimen and an acute-flare regimen have different clinical purposes.

Comparison

Colchicine belongs to a different pharmacological group from medicines that lower uric acid or block general pain pathways.

Treatment approach Main role
Colchicine Suppresses neutrophil-driven inflammation during or around a gout flare
Urate-lowering treatment Reduces uric acid burden over time and helps prevent future crystal formation
Anti-inflammatory analgesic treatment Reduces pain and inflammation through other pathways, with its own organ-specific risks

The choice depends on the timing of treatment, kidney and liver function, previous reactions, other medicines and the reason for prescribing. Colchicine is useful when the inflammatory response to urate crystals is the main target, but it does not replace long-term urate management.

What doctors say

In clinical practice, doctors often describe colchicine as a medicine where timing and dose discipline matter more than taking a larger amount. The therapeutic margin is narrow: the difference between a prescribed dose and a toxic dose can be clinically significant.

A doctor assessing Colchicine will usually review:

  • The reason for treatment.
  • Kidney and liver function.
  • Age and body frailty.
  • Current prescription medicines and supplements.
  • Previous gastrointestinal or muscle reactions.
  • Whether the goal is acute flare treatment, prevention or another specialist indication.

The World Health Organization identifies colchicine as an established medicine with important toxicity considerations. Clinical decisions therefore focus on matching the smallest suitable exposure to the treatment objective, rather than assuming that a higher dose gives a better result [2].

What customers often ask

Can Colchicine be taken with antibiotics or supplements?

Some antibiotics, including clarithromycin and erythromycin, can raise colchicine concentrations by inhibiting drug metabolism or transport. The EMA and TGA describe serious toxicity risks with certain interacting medicines, especially when kidney or liver function is impaired. Herbal products and supplements can also affect medicine handling, so their names should be included in the medication review. A 2025 clinical assessment should treat every new antibiotic as relevant before colchicine is continued.

Is Colchicine suitable for people under 18?

Use in children and adolescents depends on the diagnosis, age, body size, kidney function and specialist dosing instructions. The WHO recognises colchicine as a potent medicine requiring careful dose selection, while paediatric indications differ from adult gout treatment. A 2024 review of paediatric colchicine use supports specialist oversight for conditions such as familial Mediterranean fever. Children should never receive an adult’s leftover tablets or an adult flare regimen.

Can the Colchicine tablet be split, crushed or chewed?

The tablet should be swallowed as directed rather than crushed or chewed. Altering a tablet can make accurate dose measurement difficult, and a broken fragment may not represent half of the intended amount. The TGA’s 2024 medicine-safety principles support using the supplied dosage form as authorised, especially for medicines with a narrow therapeutic margin. If swallowing is difficult, the prescriber must select a suitable alternative plan instead of improvising with tablet fragments.

How soon can the effect of Colchicine become noticeable?

Colchicine may begin limiting inflammatory activity during the early part of a gout flare, with symptom improvement developing over the following hours or days. The timing depends on how soon treatment starts, the severity of inflammation and individual clearance of the medicine. NICE guidance on gout management supports prompt treatment of flares, while the 2024 clinical evidence base does not justify taking extra tablets when improvement is slow. Persistent or worsening pain may indicate that the treatment plan needs reassessment.

How long does a course last, and is long-term use acceptable?

The duration depends on whether Colchicine is being used for an acute flare, prevention during urate-lowering treatment or another diagnosed inflammatory condition. Long-term treatment can be appropriate for selected patients when the prescriber reviews kidney function, liver function, blood counts, muscle symptoms and interacting medicines. The TGA’s 2024 guidance and WHO both frame colchicine safety around dose, duration and patient factors rather than a single universal course length. Long-term use should not continue automatically after the original treatment objective has changed.

Can Colchicine affect driving, concentration or work with machinery?

Colchicine is not primarily a sedative, but nausea, diarrhoea, weakness, dizziness or severe illness can reduce concentration and physical control. Muscle toxicity or nerve symptoms may make machinery work unsafe even when alertness feels normal. The EMA safety information links colchicine toxicity with neuromuscular effects, and the 2023 regulatory evidence for low-dose use does not remove those warnings. Do not drive or operate machinery if symptoms impair reaction speed, balance, strength or attention.

Do you offer anonymous delivery?

Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.

Comparison

Allopurinol

Active ingredient: Allopurinol
300mg 100mg
From $ 149.52
pills
3.5 (5)

Colchicine Current

Active ingredient: Colchicine
0.5mg
From $ 195.80
pills
4.2 (3)

How the medicines for Gout compare

Sources

  1. European Medicines Agency (2018). Summary of Product Characteristics (SmPC) — colchicine.
  2. World Health Organization (2023). WHO Model List of Essential Medicines.

How Buyers Rate Colchicine

Based on 3 reviews

Neil Z., 67 Verified
Rating: 4 out of 5

500 microgram tablets, 1 day. He used colchicine during a prescribed gout-flare plan. The swelling became easier to manage within the first day, but loose stools started after the next doses, so his clinician changed the schedule.

1 day 5 Oct 2026
David, 58 Verified
Rating: 4 out of 5

500 microgram tablets, several weeks. He had taken colchicine for flare prevention while urate-lowering treatment was adjusted. After several weeks, attacks became less disruptive, although nausea made the tablets difficult on some mornings.

Several weeks 17 Oct 2026
Thomas A., 35 Verified
Rating: 4.5 out of 5

500 microgram tablets, 1 flare. He started treatment early in a flare and felt the joint settle sooner than during a previous untreated attack. He later realised that taking an extra tablet after a missed dose was unsafe and received a revised plan from his prescriber.

1 flare 31 Oct 2026
Get our free app Shop faster and track your orders 3.8 · 494 reviews Install